ATE535602T1 - Modifiziertes insulin mit reduzierter immunogenität - Google Patents
Modifiziertes insulin mit reduzierter immunogenitätInfo
- Publication number
- ATE535602T1 ATE535602T1 AT02736480T AT02736480T ATE535602T1 AT E535602 T1 ATE535602 T1 AT E535602T1 AT 02736480 T AT02736480 T AT 02736480T AT 02736480 T AT02736480 T AT 02736480T AT E535602 T1 ATE535602 T1 AT E535602T1
- Authority
- AT
- Austria
- Prior art keywords
- reduced immunogenicity
- modified insulin
- insulin
- modified
- immunogenicity
- Prior art date
Links
- 230000005847 immunogenicity Effects 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6431—Linoleic acids [18:2[n-6]]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6432—Eicosapentaenoic acids [EPA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
- C12P7/6434—Docosahexenoic acids [DHA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/769,863 US6635451B2 (en) | 2001-01-25 | 2001-01-25 | Desaturase genes and uses thereof |
US10/054,534 US7067285B2 (en) | 2001-01-25 | 2002-01-22 | Desaturase genes and uses thereof |
PCT/US2002/001924 WO2002081668A2 (en) | 2001-01-25 | 2002-01-24 | Desaturase genes and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE535602T1 true ATE535602T1 (de) | 2011-12-15 |
Family
ID=27735000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02736480T ATE535602T1 (de) | 2001-01-25 | 2002-01-24 | Modifiziertes insulin mit reduzierter immunogenität |
Country Status (8)
Country | Link |
---|---|
US (6) | US6635451B2 (de) |
EP (2) | EP2333052B1 (de) |
JP (3) | JP4347397B2 (de) |
AR (1) | AR035534A1 (de) |
AT (1) | ATE535602T1 (de) |
CA (2) | CA2698579C (de) |
ES (1) | ES2377198T3 (de) |
PT (1) | PT1392823E (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635451B2 (en) * | 2001-01-25 | 2003-10-21 | Abbott Laboratories | Desaturase genes and uses thereof |
US20050089879A1 (en) * | 2001-07-31 | 2005-04-28 | Ivo Feussner | Method for producing arachidonic acid in transgenic organisms |
DE10219203A1 (de) * | 2002-04-29 | 2003-11-13 | Basf Plant Science Gmbh | Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in Pflanzen |
EP1619960A4 (de) * | 2003-03-07 | 2009-03-18 | Advanced Bionutrition Corp | Futtermittelformulierung für land- und wasserbewohner |
DE602004021001D1 (de) | 2003-08-21 | 2009-06-18 | Monsanto Technology Llc | Fettsäuredesaturasen aus primula |
WO2005102310A1 (en) | 2004-04-16 | 2005-11-03 | Monsanto Technology Llc | Expression of fatty acid desaturases in corn |
AU2011232757B2 (en) * | 2004-04-22 | 2013-10-03 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
CN102559364B (zh) | 2004-04-22 | 2016-08-17 | 联邦科学技术研究组织 | 用重组细胞合成长链多不饱和脂肪酸 |
EP2363492A3 (de) | 2004-04-22 | 2012-03-14 | Commonwealth Scientific and Industrial Research Organisation | Synthese von langkettigen polyungesättigten Fettsäuren durch rekombinante Zellen |
US7364883B2 (en) * | 2004-05-07 | 2008-04-29 | Yeastern Biotech Co., Ltd. | Process for producing poly-unsaturated fatty acids by oleaginous yeasts |
BRPI0511236A (pt) * | 2004-06-04 | 2007-11-27 | Fluxome Sciences As | método para a produção de ácidos graxos poliinsaturados com quatro ou mais ligações duplas, saccharomyces cerevisiae geneticamente modificado que tem capacidade de produzir ácidos graxos poliinsaturados com quatro ou mais ligações duplas quando desenvolvido em um substrato que não de ácido graxo, composição, uso da composição e uso de um saccharomyces cervisiae geneticamente modificado |
US8685679B2 (en) * | 2004-11-04 | 2014-04-01 | E I Du Pont De Nemours And Company | Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms |
US7588931B2 (en) * | 2004-11-04 | 2009-09-15 | E. I. Du Pont De Nemours And Company | High arachidonic acid producing strains of Yarrowia lipolytica |
EP1863916B1 (de) * | 2005-03-16 | 2011-08-24 | Metabolix, Inc. | Chemisch induzierbare Expression von Biosynthesewegen |
JP5033122B2 (ja) | 2005-05-23 | 2012-09-26 | アルカディア バイオサイエンシズ,インコーポレイテッド | 増量ガンマ−リノレン酸を含むベニバナ |
PL2447356T3 (pl) | 2005-06-07 | 2016-10-31 | Mikroorganizmy eukariotyczne do wytwarzania lipidów i przeciwutleniaczy | |
EP1991047B1 (de) | 2006-03-01 | 2012-09-26 | Pioneer Hi-Bred International Inc. | Zusammensetzung in zusammenhang mit dem quantitative trait locus 6 (qtl6) in mais und anwendungsverfahren dafür |
US7465793B2 (en) | 2006-04-20 | 2008-12-16 | E.I. Du Pont De Nemours And Company | Synthetic Δ17 desaturase derived from Phytophthora ramourum and its use in making polyunsaturated fatty acids |
MX2009001346A (es) * | 2006-08-01 | 2009-04-17 | Ocean Nutrition Canada Ltd | Microbios productores de aceite y metodos de modificacion de los mismos. |
CA2661697A1 (en) | 2006-08-29 | 2008-03-06 | Commonwealth Scientific And Industrial Research Organisation | Synthesis of fatty acids |
DK2087105T3 (da) * | 2006-10-30 | 2015-05-26 | Du Pont | Delta 17-desaturase og anvendelse heraf ved fremstilling af flerumættede fedtsyrer |
US7943365B2 (en) | 2007-05-03 | 2011-05-17 | E.I. Du Pont De Nemours And Company | Δ-5 desaturases and their use in making polyunsaturated fatty acids |
MX2010000548A (es) * | 2007-07-13 | 2010-03-09 | Ocean Nutrition Canada Ltd | Desaturasas d4 y elongasas d5. |
JP2011529689A (ja) * | 2008-08-01 | 2011-12-15 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | Δ6デサチュラーゼおよび多価不飽和脂肪酸生成におけるそれらの使用 |
AR074364A1 (es) | 2008-11-18 | 2011-01-12 | Commw Scient Ind Res Org | Enzimas y metodo para producir acidos grasos omega -3 |
US8916154B2 (en) | 2009-04-27 | 2014-12-23 | Abbott Laboratories | Antibodies against delta-5 desaturase and uses thereof |
US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
SG10201810439SA (en) | 2012-06-15 | 2018-12-28 | Commw Scient Ind Res Org | Production of long chain polyunsaturated fatty acids in plant cells |
WO2014141098A1 (en) | 2013-03-13 | 2014-09-18 | Dsm Nutritional Products Ag | Engineering microorganisms |
BR112016014508A2 (pt) | 2013-12-18 | 2018-07-31 | Commonwealth Scientific And Industrial Research Organisation | Lipídeo compreendendo ácidos graxos poli- insaturados de cadeia longa |
US10473585B2 (en) * | 2014-06-16 | 2019-11-12 | Murphy Brown, Llc | Method and system for measuring a physical parameter of a particulate material |
SG11201610596PA (en) | 2014-06-27 | 2017-01-27 | Commw Scient Ind Res Org | Lipid comprising docosapentaenoic acid |
CN112741154A (zh) * | 2019-10-30 | 2021-05-04 | 东北农业大学 | 一种早产儿配方液态乳及其制备方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL63907A0 (en) | 1980-09-24 | 1981-12-31 | Cetus Corp | Diagnostic method and antibody probe for use therein |
ATE53862T1 (de) | 1982-01-22 | 1990-06-15 | Cetus Corp | Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel. |
US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5420034A (en) | 1986-07-31 | 1995-05-30 | Calgene, Inc. | Seed-specific transcriptional regulation |
US4943674A (en) | 1987-05-26 | 1990-07-24 | Calgene, Inc. | Fruit specific transcriptional factors |
GB8507058D0 (en) | 1985-03-19 | 1985-04-24 | Efamol Ltd | Pharmaceutical & dietary compositions |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
GB8524275D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
GB8524276D0 (en) | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
US5107065A (en) | 1986-03-28 | 1992-04-21 | Calgene, Inc. | Anti-sense regulation of gene expression in plant cells |
US5188958A (en) | 1986-05-29 | 1993-02-23 | Calgene, Inc. | Transformation and foreign gene expression in brassica species |
CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
US5004863B2 (en) | 1986-12-03 | 2000-10-17 | Agracetus | Genetic engineering of cotton plants and lines |
US5416011A (en) | 1988-07-22 | 1995-05-16 | Monsanto Company | Method for soybean transformation and regeneration |
US5130242A (en) | 1988-09-07 | 1992-07-14 | Phycotech, Inc. | Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
US5116871A (en) | 1988-09-13 | 1992-05-26 | Efamol Holdings Plc | Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis |
US5231020A (en) | 1989-03-30 | 1993-07-27 | Dna Plant Technology Corporation | Genetic engineering of novel plant phenotypes |
US5106739A (en) | 1989-04-18 | 1992-04-21 | Calgene, Inc. | CaMv 355 enhanced mannopine synthase promoter and method for using same |
US5196198A (en) | 1989-06-02 | 1993-03-23 | Abbott Laboratories | Parenteral nutrition product |
US5175095A (en) | 1989-07-19 | 1992-12-29 | Calgene, Inc. | Ovary-tissue transcriptional factors |
CA2083259C (en) | 1990-05-25 | 2007-05-15 | William D. Hitz | Nucleotide sequence of soybean stearoyl-acp desaturase gene |
US5518908A (en) | 1991-09-23 | 1996-05-21 | Monsanto Company | Method of controlling insects |
PH31293A (en) | 1991-10-10 | 1998-07-06 | Rhone Poulenc Agrochimie | Production of y-linolenic acid by a delta6-desaturage. |
DK0616644T3 (da) | 1991-12-04 | 2003-10-27 | Du Pont | Fedtsyredesaturase-gener fra planter |
US5912120A (en) | 1992-04-09 | 1999-06-15 | The United States Of America As Represented By The Department Of Health And Human Services, | Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism |
CA2149223C (en) | 1992-11-17 | 2007-04-24 | Jonathan Edward Lightner | Genes for microsomal delta-12 fatty acid desaturases and related enzymes from plants |
WO1994019477A1 (en) | 1993-02-26 | 1994-09-01 | Calgene Inc. | Geminivirus-based gene expression system |
JPH07228888A (ja) | 1994-02-17 | 1995-08-29 | Shimadzu Corp | 高度不飽和脂肪酸の精製方法 |
US5750176A (en) | 1994-03-09 | 1998-05-12 | Abbott Laboratories | Transgenic non-human mammal milk comprising 2'-fucosyl-lactose |
CA2184687A1 (en) | 1994-03-09 | 1995-09-14 | Pedro Antonio Prieto | Humanized milk |
NZ281041A (en) | 1994-03-09 | 1998-04-27 | Abbott Lab | Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk |
US5427857A (en) * | 1994-06-28 | 1995-06-27 | E. I. Du Pont De Nemours And Company | Cathodic electrocoating compositions containing branched epoxy amine resins |
US5631152A (en) | 1994-10-26 | 1997-05-20 | Monsanto Company | Rapid and efficient regeneration of transgenic plants |
US5654402A (en) | 1994-10-26 | 1997-08-05 | Michigan State University | Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase |
JPH0913077A (ja) | 1995-07-04 | 1997-01-14 | Nisshin Oil Mills Ltd:The | 臓器蓄積性の高い油脂 |
PT1598422E (pt) * | 1997-04-11 | 2013-04-03 | Abbott Lab | Métodos e composições para síntese de ácidos gordos poliinsaturados de cadeia longa em plantas |
US5972664A (en) * | 1997-04-11 | 1999-10-26 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
EP1080189A4 (de) | 1998-05-29 | 2003-01-08 | Univ Ohio | Zusammensetzungen und verfahren zur herstellung von fettsäuren, deren derivate und nachfolgende produkte |
JP2000069987A (ja) | 1998-08-28 | 2000-03-07 | Suntory Ltd | アラキドン酸含有脂質並びにジホモ−γ−リノレン酸含有脂質の製造方法 |
AU6503699A (en) | 1998-10-05 | 2000-04-26 | Abbott Laboratories | Altered fatty acid biosynthesis in insect cells using delta five desaturase |
EP1035207A1 (de) | 1999-03-09 | 2000-09-13 | MultiGene Biotech GmbH | cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie |
CN1369012A (zh) | 1999-06-07 | 2002-09-11 | 巴斯夫植物科学股份有限公司 | 角齿藓△6-乙炔酶和△6-脱饱和酶 |
JP4071622B2 (ja) * | 2000-09-28 | 2008-04-02 | バイオリジナル フード アンド サイエンス コーポレーション | 脂肪酸不飽和化酵素ファミリーのメンバーであるfad4、fad5、fad5−2およびfad6、ならびにそれらの使用方法 |
JP4347572B2 (ja) | 2001-01-25 | 2009-10-21 | アボット・ラボラトリーズ | デサチュラーゼ遺伝子とその使用 |
US6635451B2 (en) * | 2001-01-25 | 2003-10-21 | Abbott Laboratories | Desaturase genes and uses thereof |
-
2001
- 2001-01-25 US US09/769,863 patent/US6635451B2/en not_active Expired - Lifetime
-
2002
- 2002-01-22 US US10/054,534 patent/US7067285B2/en not_active Expired - Lifetime
- 2002-01-24 AT AT02736480T patent/ATE535602T1/de active
- 2002-01-24 ES ES02736480T patent/ES2377198T3/es not_active Expired - Lifetime
- 2002-01-24 CA CA2698579A patent/CA2698579C/en not_active Expired - Fee Related
- 2002-01-24 PT PT02736480T patent/PT1392823E/pt unknown
- 2002-01-24 CA CA2699611A patent/CA2699611C/en not_active Expired - Fee Related
- 2002-01-24 EP EP10185334.9A patent/EP2333052B1/de not_active Expired - Lifetime
- 2002-01-24 EP EP10184220.1A patent/EP2325300B1/de not_active Expired - Lifetime
- 2002-01-25 AR ARP020100289A patent/AR035534A1/es not_active Application Discontinuation
-
2003
- 2003-05-08 US US10/431,952 patent/US7241619B2/en not_active Expired - Fee Related
-
2007
- 2007-05-07 US US11/800,631 patent/US20090265798A1/en not_active Abandoned
-
2008
- 2008-05-13 JP JP2008125523A patent/JP4347397B2/ja not_active Expired - Fee Related
- 2008-06-11 JP JP2008152844A patent/JP4347399B2/ja not_active Expired - Fee Related
- 2008-06-11 JP JP2008152845A patent/JP4347400B2/ja not_active Expired - Fee Related
-
2010
- 2010-09-09 US US12/878,788 patent/US8143486B2/en not_active Expired - Fee Related
- 2010-09-09 US US12/878,807 patent/US8143383B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4347400B2 (ja) | 2009-10-21 |
EP2333052A1 (de) | 2011-06-15 |
CA2699611C (en) | 2013-12-10 |
JP4347397B2 (ja) | 2009-10-21 |
JP2008289479A (ja) | 2008-12-04 |
US6635451B2 (en) | 2003-10-21 |
US20090265798A1 (en) | 2009-10-22 |
ES2377198T3 (es) | 2012-03-23 |
PT1392823E (pt) | 2012-03-08 |
US20110003360A1 (en) | 2011-01-06 |
EP2325300B1 (de) | 2013-11-06 |
US7241619B2 (en) | 2007-07-10 |
US8143383B2 (en) | 2012-03-27 |
JP2008289491A (ja) | 2008-12-04 |
US7067285B2 (en) | 2006-06-27 |
US20030167525A1 (en) | 2003-09-04 |
JP4347399B2 (ja) | 2009-10-21 |
US20030190733A1 (en) | 2003-10-09 |
US20030157144A1 (en) | 2003-08-21 |
AR035534A1 (es) | 2004-06-02 |
EP2333052B1 (de) | 2013-10-09 |
CA2698579C (en) | 2013-12-10 |
CA2698579A1 (en) | 2002-10-17 |
EP2325300A1 (de) | 2011-05-25 |
US8143486B2 (en) | 2012-03-27 |
CA2699611A1 (en) | 2002-10-17 |
US20110003351A1 (en) | 2011-01-06 |
JP2008289490A (ja) | 2008-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE535602T1 (de) | Modifiziertes insulin mit reduzierter immunogenität | |
DK3210637T3 (da) | Infusionssæt | |
DK1383560T4 (da) | Infusionssæt | |
DE60327864D1 (de) | Ballondissektor mit kanüle | |
MXPA03007323A (es) | Proteinas artificiales con inmunogenicidad reducida. | |
IL165788A0 (en) | Acidic insulin preparations with improved stability | |
DE60227076D1 (de) | Hämodialysator mit verbesserter dialysatperfusion | |
DE60212048D1 (de) | Katheter mit verbesserter distaler Schubfähigkeit | |
DE60212066D1 (de) | Abgabespritze | |
DE60213194D1 (de) | Haltenadel mit flügel | |
DE60211606D1 (de) | Reissverschluss mit Endanschlag | |
DE60238111D1 (de) | Viszeralfettmesser mit tonometer | |
DE50209245D1 (de) | Neuroprotektives medikament | |
DE60200078D1 (de) | Infusionsbehälter | |
DE60306911D1 (de) | Spaltoven mit gleichmässiger heizung | |
PL362375A1 (en) | Modified leptin with reduced immunogenicity | |
DE60143148D1 (de) | En mit honigwaben | |
MXPA03007838A (es) | Interferon alfa modificado con inmunogenicidad reducida. | |
DE10196460T1 (de) | Selbstzerstör-Spritze | |
HUP0401121A3 (en) | Modified thrombopoietin with reduced immunogenicity | |
DE10111783B4 (de) | Einspritzdüse | |
HUP0303523A3 (en) | Modified insulin with reduced immunogenicity | |
DE60223642D1 (de) | Mikroschalter mit demontierbarem Verbinder | |
DE60204435D1 (de) | Spritze | |
DE60206034D1 (de) | Spritze |